CeQur announced today that it closed an oversubscribed equity financing round with proceeds of $115 million.
Lucerne, Switzerland/Marlborough, Mass.–based CeQur said in a news release that it plans to use the funds to advance the commercial plans for the CeQur Simplicity wearable insulin delivery device. The company’s plans include market development, a phased commercial launch with a limited market release in 2021 and the scale-up of high-volume manufacturing.
Get the full story at our sister site, Drug Delivery Business News.